×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
MNPR – monopar therapeutics inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
MNPR
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/30
08:02 am
mnpr
Monopar Therapeutics (MNPR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $100.00 price target on the stock.
Medium
Report
Monopar Therapeutics (MNPR) had its "buy" rating reaffirmed by Chardan Capital. They now have a $100.00 price target on the stock.
3/27
04:51 pm
mnpr
Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16 [Seeking Alpha]
Low
Report
Monopar Therapeutics GAAP EPS of -$0.61 misses by $0.16 [Seeking Alpha]
3/27
01:00 pm
mnpr
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
Low
Report
Monopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update
3/2
08:00 am
mnpr
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
Medium
Report
Monopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy Officer
2/23
08:04 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
2/2
08:05 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $104.00 price target on the stock.
1/29
08:27 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock.
Medium
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $100.00 price target on the stock.
1/21
10:12 am
mnpr
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
Monopar Therapeutics (NASDAQ:MNPR) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/2
03:04 pm
mnpr
Form 4 Monopar Therapeutics For: Mar 31 Filed by: Robinson Chandler
Low
Report
Form 4 Monopar Therapeutics For: Mar 31 Filed by: Robinson Chandler
4/2
03:03 pm
mnpr
Form 4 Monopar Therapeutics For: Mar 31 Filed by: Cittadine Andrew
Low
Report
Form 4 Monopar Therapeutics For: Mar 31 Filed by: Cittadine Andrew
4/1
12:24 pm
mnpr
Form 10-K/A Monopar Therapeutics For: Dec 31
Medium
Report
Form 10-K/A Monopar Therapeutics For: Dec 31
3/27
01:27 pm
mnpr
Form 8-K Monopar Therapeutics For: Mar 27
Medium
Report
Form 8-K Monopar Therapeutics For: Mar 27
3/27
01:01 pm
mnpr
Form 10-K Monopar Therapeutics For: Dec 31
Low
Report
Form 10-K Monopar Therapeutics For: Dec 31
3/4
05:26 pm
mnpr
Form 4 Monopar Therapeutics For: Mar 02 Filed by: Rodriguez Susan
Low
Report
Form 4 Monopar Therapeutics For: Mar 02 Filed by: Rodriguez Susan
3/4
05:25 pm
mnpr
Form 3 Monopar Therapeutics For: Mar 02 Filed by: Rodriguez Susan
Low
Report
Form 3 Monopar Therapeutics For: Mar 02 Filed by: Rodriguez Susan
3/2
08:01 am
mnpr
Form 8-K Monopar Therapeutics For: Mar 02
Medium
Report
Form 8-K Monopar Therapeutics For: Mar 02
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/18
Monopar Therapeutics Inc. Announces Pricing of Initial Public Offering
217.4%
12/19 Form 424B4 Monopar Therapeutics 3.1%
4/29 Form DEFA14A Monopar Therapeutics 3.0%
4/18 Monopar Therapeutics Inc. (NASDAQ: MNPR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock. 1.5%
2/19 Monopar Therapeutics Inc. (NASDAQ: MNPR) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $42.00 price target on the stock. 1.4%
12/19 Form 424B4 Monopar Therapeutics 3.1%
4/29 Form DEFA14A Monopar Therapeutics 3.0%
4/18 Monopar Therapeutics Inc. (NASDAQ: MNPR) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $9.00 price target on the stock. 1.5%
2/19 Monopar Therapeutics Inc. (NASDAQ: MNPR) is now covered by analysts at Brookline Capital Management. They set a "buy" rating and a $42.00 price target on the stock. 1.4%
TOP News Decliners
12/20
Monopar Therapeutics Inc. Announces Full Exercise of Over-Allotment by Underwriters
-19.5%
2/20 Form 4 Monopar Therapeutics For: Jan 31 Filed by: STARR CHRISTOPHER M -9.5%
2/18 Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma -7.5%
1/13 Form 424B5 Monopar Therapeutics -5.7%
1/3 Form S-8 Monopar Therapeutics -4.1%
3/27 Q4/2019 12/31/2019 EPS -0.130 ZacksConsensus N/A ActVsEst N/A - N/A -2.9%
1/7 Form 8-K Monopar Therapeutics For: Jan 07 -1.4%
4/1 Form 4 Monopar Therapeutics For: Mar 31 Filed by: Anderson Raymond -1.0%
4/30 Monopar Therapeutics Inc. (NASDAQ: MNPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.3%
4/21 Monopar Therapeutics Inc. (NASDAQ: MNPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.2%
2/20 Form 4 Monopar Therapeutics For: Jan 31 Filed by: STARR CHRISTOPHER M -9.5%
2/18 Monopar Therapeutics Receives Orphan Drug Designation from the European Commission for Camsirubicin in the Treatment of Soft Tissue Sarcoma -7.5%
1/13 Form 424B5 Monopar Therapeutics -5.7%
1/3 Form S-8 Monopar Therapeutics -4.1%
3/27 Q4/2019 12/31/2019 EPS -0.130 ZacksConsensus N/A ActVsEst N/A - N/A -2.9%
1/7 Form 8-K Monopar Therapeutics For: Jan 07 -1.4%
4/1 Form 4 Monopar Therapeutics For: Mar 31 Filed by: Anderson Raymond -1.0%
4/30 Monopar Therapeutics Inc. (NASDAQ: MNPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.3%
4/21 Monopar Therapeutics Inc. (NASDAQ: MNPR) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -0.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: